Hemostemix (CVE:HEM) Stock Price Down 22.9% – What’s Next?

Hemostemix Inc. (CVE:HEM) traded down 22.9% during mid-day trading on Friday . The company traded as low as C$0.18 and last traded at C$0.19. 504,239 shares changed hands during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.

Hemostemix Price Performance

The company’s 50 day simple moving average is C$0.19 and its 200 day simple moving average is C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock has a market cap of C$28.42 million, a P/E ratio of -5.69 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.